){kind=logo}
May 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by…
)
Kineticos Portfolio Company, Inceptor Bio, Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma…
){kind=logo}
Kineticos Launches Kinvard Bio to Advance Next-Generation Antibiotics in the Fight Against Antimicrobial Resistance Raleigh, North Carolina – February 24,…
Steve Gelone Joins Kineticos as a Strategic Advisor for Kineticos AMR Accelerator Fund I (KAMRA I) Raleigh, North Carolina –…
Lloyd Payne Joins Kineticos as Venture Partner for Kineticos AMR Accelerator Fund I (KAMRA I) Raleigh, North Carolina – January…
){kind=logo}
Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund COLUMBUS, Ohio – January 28, 2025 – Clarametyx Biosciences Inc. (“Clarametyx”), a clinical…
Kincell Bio Welcomes Industry Veteran Mark R. Bamforth as Chief Executive Officer to Drive Business Growth Research Triangle Park,…
INCATE and Kineticos extend partnership to support startups combating Antimicrobial Resistance December 16, 2024 – INCATE (the INCubator for Antibacterial Therapies…
Kineticos Portfolio Company Inceptor Bio Announces Strategic Partnership for Next-Generation Solid Tumor CAR-T December 18, 2024 –Inceptor Bio, a leading…